Drugs / Olea Europaea
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03676309 Comparator | Sep 2017 → Mar 2018 | type 2 diabetes mellitus, vascular disorder | Villa dei Gerani | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olea Europaea | “nutraceuticals (bergamot 450 mg, Gymnema (400 mg, Phaseolamin 30 mg, Olea Europaea 10 mg)” NCT03676309 ↗ |
| Known as | Oleuropeina | “Oleuropeina (Olea Europaea) is also characterized by a peculiar polyphenolic profile.” NCT03676309 ↗ |